Yahoo Finance • 3 months ago
We recently published a list of 10 Best Australian Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Mesoblast (NASDAQ:MESO) stands against the other Australian stocks. A Look at Australia’s Eco... Full story
Yahoo Finance • 10 months ago
In this piece, we will take a look at the ten best Australian stocks to buy. If you want to skip our coverage of some of the biggest stocks in Australia and how you might trade them, then you can skip ahead to 5 Best Australian Stocks To B... Full story
Yahoo Finance • 12 months ago
NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has filed for orphan drug designation (ODD) and rare... Full story
Yahoo Finance • last year
NEW YORK, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO). Such investors are advised to contact Robert S. Willoughby at n... Full story
Yahoo Finance • 2 years ago
Mesoblast Limited Mesoblast Financial and Operational Highlights for Quarter Ended March 31, 2023 NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for i... Full story
Yahoo Finance • 2 years ago
Mesoblast Limited NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results... Full story
Yahoo Finance • 2 years ago
Key Points: Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recently published studies of ch... Full story
Yahoo Finance • 2 years ago
NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended September 30,... Full story
Yahoo Finance • 2 years ago
Mesoblast Limited Chronic Low Back Pain due to Degenerative Disc Disease NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will... Full story
Yahoo Finance • 3 years ago
WHITE PLAINS, N.Y., May 23, 2022 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announce that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlem... Full story